Related Experiment Videos

Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk

Colomba Falcone1, Maria Paola Buzzi, Sara Bozzini

  • 1Interdepartmental Center of Research in Molecular Medicine, University of Pavia, Italy. colomba.falcone@unipv.it

Journal of Nephrology
|November 14, 2012
PubMed

Insights

This study found that high-sensitivity C-reactive protein (hs-CRP), soluble form of the receptor for advanced glycation end products (sRAGE), and eotaxin-3 are reliable cardiovascular risk markers. However, these markers appear to be unrelated to each other in hypertensive patients.

Area of Science:

  • Biomedical research
  • Cardiovascular medicine
  • Nephrology

Background:

  • Cardiovascular disease (CVD) is a major cause of death, particularly in patients with kidney disease.
  • Chronic kidney disease and traditional risk factors exacerbate CVD risk, necessitating improved risk stratification.
  • Novel biomarkers are sought to enhance cardiovascular risk assessment beyond existing scores.

Purpose of the Study:

  • To investigate the relationship between novel vascular inflammation biomarkers (sRAGE and eotaxin-3) and C-reactive protein (CRP).
  • To assess these biomarkers in hypertensive patients at high cardiovascular risk.

Main Methods:

  • Plasma levels of soluble form of the receptor for advanced glycation end products (sRAGE), high-sensitivity C-reactive protein (hs-CRP), and eotaxin-3 were measured.
  • The study included 399 hypertensive patients with diabetes mellitus, metabolic syndrome, or organ damage.

Main Results:

  • No significant differences in sRAGE, eotaxin-3, or hs-CRP levels were observed between diabetic and nondiabetic subjects.
  • Univariate analysis revealed no association between plasma sRAGE or eotaxin-3 levels and hs-CRP in any subgroup.

Conclusions:

  • C-reactive protein (CRP) is confirmed as a significant marker of vascular inflammation.
  • Soluble form of the receptor for advanced glycation end products (sRAGE) and eotaxin-3 may be involved in cardiovascular diseases.
  • hs-CRP, sRAGE, and eotaxin-3 are proposed as reliable but independent cardiovascular risk markers.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...